XORTX Therapeutics Inc. (XRTX) Form 6-K — Sep 4, 2026

XORTX Therapeutics re-engaged IR Agency LLC on September 2, 2026 under a revised consulting agreement that pays the marketing firm US$2,500,000 in advance for up to ten news distribution campaigns over a three-month term beginning September 3, 2026. The fee is fully earned on receipt and non-refundable, including upon termination. The new deal follows a winding path: the original May 13, 2026 IR agreement was tied to the company's US$5,000,000 public offering completed May 19, 2026, was terminated and rescinded effective August 7, 2026, and the full US$2,500,000 was returned to XORTX on August 14, 2026. The re-engagement fee is being funded from those returned and reserved amounts.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.